Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Green Cross Corp KoreafiledCriticalGreen Cross Corp Japan
Priority to JP11029580ApriorityCriticalpatent/JPS5735521A/en
Publication of JPS5735521ApublicationCriticalpatent/JPS5735521A/en
Publication of JPS6236486B2publicationCriticalpatent/JPS6236486B2/ja
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Peptides Or Proteins
(AREA)
Abstract
PURPOSE: To leave a mold substance and exothermic substance in a supernatant liquid and to remove these substance from an aqueous solution containing plasma protein, by adding an aluminum salt and zinc salt to an aqueous solution containing human albumin and/or γ-globulin, so that plasma protein is precipitated.
CONSTITUTION: An aluminum salt (e.g., alum, aluminum sulfate, etc.) in an amount to make the final concentration 0.05W10mM and a zinc salt (e.g., zinc acetate, zinc sulfate, etc.) in an amount to give the final concentration 0.5W100mM are added to an aqueous solution containing human albumin and/or γ-globulin (e.g., human blood, serum, the placenta, etc.), so that plasma protein is precipitated. Simultaneously, a mold substance and exothermic substance admixed in it are left in the supernatant liquid, so that these substances are removed from human plasma protein economically by a safe method completely. The reaction temperature is 0W35°C, preferably 4W25°C.
COPYRIGHT: (C)1982,JPO&Japio
JP11029580A1980-08-131980-08-13Fractionation of plasma protein
GrantedJPS5735521A
(en)
Derivatives of cis, endo-2-azabicyclo- (3,3,0) -octane-3-carboxylic acid, process for the preparation thereof, agents containing these substances and their use.